Fig. 5: MEG3 inhibits nucear localization of PKM2. | Cell Death & Disease

Fig. 5: MEG3 inhibits nucear localization of PKM2.

From: Long noncoding RNA MEG3 suppresses liver cancer cells growth through inhibiting β-catenin by activating PKM2 and inactivating PTEN

Fig. 5

A Western blotting analysis with anti-ERK1/2 in liver cancer cells Hep3B cell lines transfected with pCMV6-A-GFP, pCMV6-A-GFP-MEG3, respectively. β-actin as an internal control. B Co-immunoprecipitation (IP) with anti-ERK1/2 followed by Western blotting with anti-pPKM2(Ile 429/Leu 431) in the Hep3B cell lines transfected with pCMV6-A-GFP, pCMV6-A-GFP-MEG3, respectively. IgG IP as negative control. INPUT refers to Western blotting with anti-pPKM2(Ile 429/Leu 431). C Western blotting analysis with anti-pPKM2(ser37) in liver cancer cells Hep3B cell lines transfected with pCMV6-A-GFP, pCMV6-A-GFP-MEG3, respectively. β-actin as an internal control. D Western blotting analysis with anti-PKM2 in liver cancer cells Hep3B cell lines transfected with pCMV6-A-GFP, pCMV6-A-GFP-MEG3, respectively (nuclear and plasmic protein). LMNB1 (nuclear protein) or β-actin as an internal control. E Immunofluoresence staining (IFS) with anti-PKM2 in liver cancer cells Hep3B cell lines transfected with pCMV6-A-GFP, pCMV6-A-GFP-MEG3, respectively; scale bars,100 μm

Back to article page